METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer
Chemoresistance is a main reason for therapeutic failure and poor prognosis for breast cancer (BC) patients, especially for triple-negative BC patients. How the molecular mechanisms underlying the chemoresistance to doxorubicin (Dox) in BC is not well understood. Here, we revealed that METTL3/IGF2BP...
Saved in:
| Published in | Biochimica et biophysica acta. General subjects Vol. 1868; no. 3; p. 130542 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
01.03.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Chemoresistance is a main reason for therapeutic failure and poor prognosis for breast cancer (BC) patients, especially for triple-negative BC patients. How the molecular mechanisms underlying the chemoresistance to doxorubicin (Dox) in BC is not well understood. Here, we revealed that METTL3/IGF2BP3-regulated m6A modification of HYOU1 increased Dox resistance in BC cells. CCK-8 and Annexin V-FITC/PI staining assays were employed to measure viability and cell death. Western blotting and qRT-PCR assays were applied to assay the expression of genes. Knockdown and rescue experiments were used to assay the role of METTL3, IGF2BP3 and HYOU1 in regulating BC cell responses to Dox. RIP, MeRIP and dual-luciferase activity assays were applied to examine the function of METTL3/IGF2BP3 in the m6A modification of HYOU1 mRNA. It was found that global mRNA m6A methylation levels were upregulated in Dox-resistant BC cell lines. The methyltransferase METTL3 was upregulated in Dox-resistant BC cell lines, and downregulation of METTL3 could overcome this resistance. Furthermore, HYOU1 was identified as a downstream target of METTL3-mediated m6A modification. Downregulation of HYOU1 could overcome Dox resistance, while forced expression of HYOU1 resulted in Dox resistance in BC cells. METTL3 cooperated with IGF2BP3 to modulate the m6A modification of HYOU1 mRNA and increase its stability. Collectively, our findings unveiled the key roles of the METTL3/IGF2BP3/HYOU1 axis in modulating Dox sensitivity in BC cells; thus, targeting this axis might be a potential strategy to increase Dox efficacy in the treatment of BC. |
|---|---|
| AbstractList | Chemoresistance is a main reason for therapeutic failure and poor prognosis for breast cancer (BC) patients, especially for triple-negative BC patients. How the molecular mechanisms underlying the chemoresistance to doxorubicin (Dox) in BC is not well understood. Here, we revealed that METTL3/IGF2BP3-regulated m6A modification of HYOU1 increased Dox resistance in BC cells. CCK-8 and Annexin V-FITC/PI staining assays were employed to measure viability and cell death. Western blotting and qRT-PCR assays were applied to assay the expression of genes. Knockdown and rescue experiments were used to assay the role of METTL3, IGF2BP3 and HYOU1 in regulating BC cell responses to Dox. RIP, MeRIP and dual-luciferase activity assays were applied to examine the function of METTL3/IGF2BP3 in the m6A modification of HYOU1 mRNA. It was found that global mRNA m6A methylation levels were upregulated in Dox-resistant BC cell lines. The methyltransferase METTL3 was upregulated in Dox-resistant BC cell lines, and downregulation of METTL3 could overcome this resistance. Furthermore, HYOU1 was identified as a downstream target of METTL3-mediated m6A modification. Downregulation of HYOU1 could overcome Dox resistance, while forced expression of HYOU1 resulted in Dox resistance in BC cells. METTL3 cooperated with IGF2BP3 to modulate the m6A modification of HYOU1 mRNA and increase its stability. Collectively, our findings unveiled the key roles of the METTL3/IGF2BP3/HYOU1 axis in modulating Dox sensitivity in BC cells; thus, targeting this axis might be a potential strategy to increase Dox efficacy in the treatment of BC.Chemoresistance is a main reason for therapeutic failure and poor prognosis for breast cancer (BC) patients, especially for triple-negative BC patients. How the molecular mechanisms underlying the chemoresistance to doxorubicin (Dox) in BC is not well understood. Here, we revealed that METTL3/IGF2BP3-regulated m6A modification of HYOU1 increased Dox resistance in BC cells. CCK-8 and Annexin V-FITC/PI staining assays were employed to measure viability and cell death. Western blotting and qRT-PCR assays were applied to assay the expression of genes. Knockdown and rescue experiments were used to assay the role of METTL3, IGF2BP3 and HYOU1 in regulating BC cell responses to Dox. RIP, MeRIP and dual-luciferase activity assays were applied to examine the function of METTL3/IGF2BP3 in the m6A modification of HYOU1 mRNA. It was found that global mRNA m6A methylation levels were upregulated in Dox-resistant BC cell lines. The methyltransferase METTL3 was upregulated in Dox-resistant BC cell lines, and downregulation of METTL3 could overcome this resistance. Furthermore, HYOU1 was identified as a downstream target of METTL3-mediated m6A modification. Downregulation of HYOU1 could overcome Dox resistance, while forced expression of HYOU1 resulted in Dox resistance in BC cells. METTL3 cooperated with IGF2BP3 to modulate the m6A modification of HYOU1 mRNA and increase its stability. Collectively, our findings unveiled the key roles of the METTL3/IGF2BP3/HYOU1 axis in modulating Dox sensitivity in BC cells; thus, targeting this axis might be a potential strategy to increase Dox efficacy in the treatment of BC. Chemoresistance is a main reason for therapeutic failure and poor prognosis for breast cancer (BC) patients, especially for triple-negative BC patients. How the molecular mechanisms underlying the chemoresistance to doxorubicin (Dox) in BC is not well understood. Here, we revealed that METTL3/IGF2BP3-regulated m6A modification of HYOU1 increased Dox resistance in BC cells. CCK-8 and Annexin V-FITC/PI staining assays were employed to measure viability and cell death. Western blotting and qRT-PCR assays were applied to assay the expression of genes. Knockdown and rescue experiments were used to assay the role of METTL3, IGF2BP3 and HYOU1 in regulating BC cell responses to Dox. RIP, MeRIP and dual-luciferase activity assays were applied to examine the function of METTL3/IGF2BP3 in the m6A modification of HYOU1 mRNA. It was found that global mRNA m6A methylation levels were upregulated in Dox-resistant BC cell lines. The methyltransferase METTL3 was upregulated in Dox-resistant BC cell lines, and downregulation of METTL3 could overcome this resistance. Furthermore, HYOU1 was identified as a downstream target of METTL3-mediated m6A modification. Downregulation of HYOU1 could overcome Dox resistance, while forced expression of HYOU1 resulted in Dox resistance in BC cells. METTL3 cooperated with IGF2BP3 to modulate the m6A modification of HYOU1 mRNA and increase its stability. Collectively, our findings unveiled the key roles of the METTL3/IGF2BP3/HYOU1 axis in modulating Dox sensitivity in BC cells; thus, targeting this axis might be a potential strategy to increase Dox efficacy in the treatment of BC. |
| ArticleNumber | 130542 |
| Author | Zhang, Jianan Zhou, Shaocheng Wang, Lei Zhang, Lin Sheng, Lijuan |
| Author_xml | – sequence: 1 givenname: Shaocheng surname: Zhou fullname: Zhou, Shaocheng – sequence: 2 givenname: Lijuan surname: Sheng fullname: Sheng, Lijuan – sequence: 3 givenname: Lin surname: Zhang fullname: Zhang, Lin – sequence: 4 givenname: Jianan surname: Zhang fullname: Zhang, Jianan – sequence: 5 givenname: Lei surname: Wang fullname: Wang, Lei |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38103759$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kT9P5DAQxS0EgoW7b4CQS5ostsdxkusA8U9axBVLcZVlO2PkVRJzdiLBt7_sLTQUTDMa6feeNO8dk_0hDkjIKWdLzri62CytNS84LAUTsOTASin2yILXlShqxtQ-WTBgspBclUfkOOcNm6dsykNyBDVnUJXNgtjHm_V6BRcPd7fi6jcUCV-mzozY0l5d0j62wQdnxhAHGj29__P0zKmLg8eUaRvfYppscGGgCXPIoxkc0vmyCU0eqdve6Qc58KbL-PNjn5Dn25v19X2xerp7uL5cFQ5YNRZVK60HA5ZbqKQC5Vulam9lU_sKm_kNybACXznbSOOY9Fa03KBpS_AzCSfkfOf7muLfCfOo-5Addp0ZME5Zi4YBCFUKmNGzD3SyPbb6NYXepHf9mcsM_NoBLsWcE3rtwvg_hjGZ0GnO9LYEvdG7EvS2BL0rYRbLL-JP_29l_wCGY4vT |
| CitedBy_id | crossref_primary_10_1007_s11033_024_10138_y crossref_primary_10_1002_cam4_70410 crossref_primary_10_1002_jbt_70162 crossref_primary_10_1002_jgm_70014 crossref_primary_10_1016_j_intimp_2024_113780 crossref_primary_10_1186_s13058_024_01869_8 |
| Cites_doi | 10.1016/j.anndiagpath.2017.05.015 10.1016/j.biopha.2023.114846 10.1111/jcmm.13118 10.1186/s12943-023-01810-1 10.1186/s12885-019-5538-z 10.1046/j.1464-410X.2002.02915.x 10.1016/j.trecan.2023.04.003 10.7150/jca.13695 10.1038/onc.2015.164 10.1080/15592294.2023.2217033 10.1007/s11010-016-2711-4 10.1016/j.gene.2019.144076 10.1186/s12943-021-01447-y 10.3322/caac.21754 10.1074/jbc.271.9.5025 10.1038/s41598-022-20477-0 10.1186/s40364-023-00499-0 10.1210/jc.2010-1043 10.3390/ph16060802 10.1074/jbc.C112.442319 10.1016/j.canep.2009.10.003 10.1158/0008-5472.CAN-05-2609 10.1002/jbt.22922 10.1007/s00018-012-1186-z 10.1007/s11033-022-07978-x 10.1016/j.molcel.2020.06.017 10.1016/j.bbamcr.2021.118951 10.1128/JVI.00511-14 10.1172/JCI118994 10.1016/j.cbpc.2015.12.005 10.1186/s13046-021-02088-1 10.1002/tox.22656 10.1186/s12943-023-01782-2 10.1080/21645515.2019.1571892 10.7150/ijbs.81000 10.1091/mbc.E16-01-0033 10.2147/OTT.S297332 10.1186/s12943-019-1109-9 10.1111/aos.13600 10.1016/j.canlet.2020.04.003 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023. Published by Elsevier B.V. |
| Copyright_xml | – notice: Copyright © 2023. Published by Elsevier B.V. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.bbagen.2023.130542 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Biology |
| EISSN | 1872-8006 |
| ExternalDocumentID | 38103759 10_1016_j_bbagen_2023_130542 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO AAYXX ABEFU ABFNM ABGSF ABMAC ABUDA ABWVN ABXDB ACDAQ ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AEUPX AFJKZ AFPUW AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRDE AGRNS AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CITATION CS3 EBS EFJIC EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HLW HVGLF HZ~ IHE J1W KOM LX3 M41 MO0 N9A O-L O9- OAUVE OHT OZT P-8 P-9 PC. Q38 R2- ROL RPZ SBG SCC SDF SDG SDP SES SEW SPCBC SSH SSU SSZ T5K UQL WH7 WUQ XJT XPP ~G- CGR CUY CVF ECM EFKBS EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c307t-7d4bf3a3b1b374636fd668fb498f7e941640e73f7cb94ac04fb2d1aead53f6683 |
| ISSN | 0304-4165 1872-8006 |
| IngestDate | Tue Aug 05 09:05:29 EDT 2025 Mon Jul 21 06:02:01 EDT 2025 Tue Jul 01 00:22:19 EDT 2025 Thu Apr 24 22:58:48 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | m6A modification Chemoresistance METTL3 Breast cancer HYOU1 IGF2BP3 Doxorubicin |
| Language | English |
| License | Copyright © 2023. Published by Elsevier B.V. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c307t-7d4bf3a3b1b374636fd668fb498f7e941640e73f7cb94ac04fb2d1aead53f6683 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 38103759 |
| PQID | 2903326523 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2903326523 pubmed_primary_38103759 crossref_citationtrail_10_1016_j_bbagen_2023_130542 crossref_primary_10_1016_j_bbagen_2023_130542 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-03-00 20240301 |
| PublicationDateYYYYMMDD | 2024-03-01 |
| PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Biochimica et biophysica acta. General subjects |
| PublicationTitleAlternate | Biochim Biophys Acta Gen Subj |
| PublicationYear | 2024 |
| References | Inoue (10.1016/j.bbagen.2023.130542_bb0045) 2016; 27 Ohashi (10.1016/j.bbagen.2023.130542_bb0195) 2017; 31 Li (10.1016/j.bbagen.2023.130542_bb0040) 2022; 36 Giaquinto (10.1016/j.bbagen.2023.130542_bb0010) 2022; 72 Wang (10.1016/j.bbagen.2023.130542_bb0120) 2023; 163 Tsukamoto (10.1016/j.bbagen.2023.130542_bb0155) 1998; 78 Zhu (10.1016/j.bbagen.2023.130542_bb0185) 2023; 11 Huang (10.1016/j.bbagen.2023.130542_bb0055) 2019; 34 Giffin (10.1016/j.bbagen.2023.130542_bb0150) 2014; 88 Abu El-Asrar (10.1016/j.bbagen.2023.130542_bb0060) 2018; 96 Park (10.1016/j.bbagen.2023.130542_bb0170) 2006; 66 Maughan (10.1016/j.bbagen.2023.130542_bb0015) 2010; 81 Tsukamoto (10.1016/j.bbagen.2023.130542_bb0065) 1996; 98 Gao (10.1016/j.bbagen.2023.130542_bb0165) 2010; 95 Coughlin (10.1016/j.bbagen.2023.130542_bb0005) 2009; 33 He (10.1016/j.bbagen.2023.130542_bb0025) 2019; 18 Wang (10.1016/j.bbagen.2023.130542_bb0080) 2023; 50 Samuels (10.1016/j.bbagen.2023.130542_bb0180) 2020 Samanta (10.1016/j.bbagen.2023.130542_bb0190) 2016; 35 Pomaville (10.1016/j.bbagen.2023.130542_bb0030) 2023; 9 Wang (10.1016/j.bbagen.2023.130542_bb0135) 2020; 722 Hao (10.1016/j.bbagen.2023.130542_bb0075) 2021; 1868 Zhou (10.1016/j.bbagen.2023.130542_bb0115) 2023; 18 Lee (10.1016/j.bbagen.2023.130542_bb0095) 2023; 16 Yao (10.1016/j.bbagen.2023.130542_bb0100) 2020; 483 Chen (10.1016/j.bbagen.2023.130542_bb0105) 2023; 19 Liu (10.1016/j.bbagen.2023.130542_bb0220) 2017; 21 Zhuang (10.1016/j.bbagen.2023.130542_bb0110) 2023; 22 Nie (10.1016/j.bbagen.2023.130542_bb0085) 2021; 40 Zhang (10.1016/j.bbagen.2023.130542_bb0125) 2020; 79 Wu (10.1016/j.bbagen.2023.130542_bb0130) 2019; 19 Yuan (10.1016/j.bbagen.2023.130542_bb0090) 2016; 181-182 Bell (10.1016/j.bbagen.2023.130542_bb0175) 2013; 70 Jiang (10.1016/j.bbagen.2023.130542_bb0210) 2019; 15 Zhou (10.1016/j.bbagen.2023.130542_bb0140) 2016; 7 Li (10.1016/j.bbagen.2023.130542_bb0205) 2023 Wan (10.1016/j.bbagen.2023.130542_bb0215) 2022; 21 Rao (10.1016/j.bbagen.2023.130542_bb0070) 2021; 14 Samanta (10.1016/j.bbagen.2023.130542_bb0200) 2013; 288 Asahi (10.1016/j.bbagen.2023.130542_bb0145) 2002; 90 Jing (10.1016/j.bbagen.2023.130542_bb0035) 2022; 12 Kuwabara (10.1016/j.bbagen.2023.130542_bb0050) 1996; 271 Wang (10.1016/j.bbagen.2023.130542_bb0020) 2023; 22 Kretowski (10.1016/j.bbagen.2023.130542_bb0160) 2016; 417 |
| References_xml | – volume: 31 start-page: 30 year: 2017 ident: 10.1016/j.bbagen.2023.130542_bb0195 article-title: IMP3 contributes to poor prognosis of patients with metaplastic breast carcinoma: a clinicopathological study publication-title: Ann. Diagn. Pathol. doi: 10.1016/j.anndiagpath.2017.05.015 – volume: 163 year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0120 article-title: N6-methyladenosine (m6A) in cancer stem cell: from molecular mechanisms to therapeutic implications publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2023.114846 – volume: 21 start-page: 1979 issue: 9 year: 2017 ident: 10.1016/j.bbagen.2023.130542_bb0220 article-title: CD44(+) fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling publication-title: J. Cell. Mol. Med. doi: 10.1111/jcmm.13118 – volume: 22 start-page: 102 issue: 1 year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0020 article-title: Epigenetic modification of m(6)a regulator proteins in cancer publication-title: Mol. Cancer doi: 10.1186/s12943-023-01810-1 – volume: 19 start-page: 326 issue: 1 year: 2019 ident: 10.1016/j.bbagen.2023.130542_bb0130 article-title: Changes of N6-methyladenosine modulators promote breast cancer progression publication-title: BMC Cancer doi: 10.1186/s12885-019-5538-z – volume: 90 start-page: 462 issue: 4 year: 2002 ident: 10.1016/j.bbagen.2023.130542_bb0145 article-title: Immunohistochemical detection of the 150-kDa oxygen-regulated protein in bladder cancer publication-title: BJU Int. doi: 10.1046/j.1464-410X.2002.02915.x – volume: 9 start-page: 528 issue: 7 year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0030 article-title: Advances in targeting RNA modifications for anticancer therapy publication-title: Trends Cancer doi: 10.1016/j.trecan.2023.04.003 – volume: 7 start-page: 367 issue: 4 year: 2016 ident: 10.1016/j.bbagen.2023.130542_bb0140 article-title: HYOU1, regulated by LPLUNC1, is up-regulated in nasopharyngeal carcinoma and associated with poor prognosis publication-title: J. Cancer doi: 10.7150/jca.13695 – volume: 35 start-page: 1111 issue: 9 year: 2016 ident: 10.1016/j.bbagen.2023.130542_bb0190 article-title: IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG publication-title: Oncogene doi: 10.1038/onc.2015.164 – year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0205 article-title: Association of the m(6) a reader IGF2BP3 with tumor progression and brain-specific metastasis in breast cancer publication-title: Cancer – volume: 18 start-page: 2217033 issue: 1 year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0115 article-title: METTL3-mediated m(6)a modification of lnc KCNQ1OT1 promotes doxorubicin resistance in breast cancer by regulating miR-103a-3p/MDR1 axis publication-title: Epigenetics doi: 10.1080/15592294.2023.2217033 – volume: 78 start-page: 699 issue: 6 year: 1998 ident: 10.1016/j.bbagen.2023.130542_bb0155 article-title: Expression of the 150-kd oxygen-regulated protein in human breast cancer publication-title: Lab. Investig. – volume: 417 start-page: 35 issue: 1–2 year: 2016 ident: 10.1016/j.bbagen.2023.130542_bb0160 article-title: Low glucose dependent decrease of apoptosis and induction of autophagy in breast cancer MCF-7 cells publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-016-2711-4 – volume: 722 year: 2020 ident: 10.1016/j.bbagen.2023.130542_bb0135 article-title: N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2 publication-title: Gene doi: 10.1016/j.gene.2019.144076 – volume: 21 start-page: 60 issue: 1 year: 2022 ident: 10.1016/j.bbagen.2023.130542_bb0215 article-title: METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer publication-title: Mol. Cancer doi: 10.1186/s12943-021-01447-y – volume: 72 start-page: 524 issue: 6 year: 2022 ident: 10.1016/j.bbagen.2023.130542_bb0010 article-title: Breast Cancer statistics, 2022 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21754 – volume: 81 start-page: 1339 issue: 11 year: 2010 ident: 10.1016/j.bbagen.2023.130542_bb0015 article-title: Treatment of breast cancer publication-title: Am. Fam. Physician – volume: 271 start-page: 5025 issue: 9 year: 1996 ident: 10.1016/j.bbagen.2023.130542_bb0050 article-title: Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain publication-title: J. Biol. Chem. doi: 10.1074/jbc.271.9.5025 – volume: 12 start-page: 16715 issue: 1 year: 2022 ident: 10.1016/j.bbagen.2023.130542_bb0035 article-title: METTL3/LINC00662/miR-186-5p feedback loop regulates docetaxel resistance in triple negative breast cancer publication-title: Sci. Rep. doi: 10.1038/s41598-022-20477-0 – volume: 11 start-page: 62 issue: 1 year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0185 article-title: Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential publication-title: Biomark Res. doi: 10.1186/s40364-023-00499-0 – volume: 95 start-page: E319 issue: 11 year: 2010 ident: 10.1016/j.bbagen.2023.130542_bb0165 article-title: Implication of oxygen-regulated protein 150 (ORP150) in apoptosis induced by proteasome inhibitors in human thyroid cancer cells publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2010-1043 – volume: 16 issue: 6 year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0095 article-title: Recent advances in doxorubicin formulation to enhance pharmacokinetics and tumor targeting publication-title: Pharmaceuticals (Basel) doi: 10.3390/ph16060802 – volume: 288 start-page: 12569 issue: 18 year: 2013 ident: 10.1016/j.bbagen.2023.130542_bb0200 article-title: IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression publication-title: J. Biol. Chem. doi: 10.1074/jbc.C112.442319 – volume: 33 start-page: 315 issue: 5 year: 2009 ident: 10.1016/j.bbagen.2023.130542_bb0005 article-title: Breast cancer as a global health concern publication-title: Cancer Epidemiol. doi: 10.1016/j.canep.2009.10.003 – volume: 66 start-page: 1161 issue: 2 year: 2006 ident: 10.1016/j.bbagen.2023.130542_bb0170 article-title: Chaperoning function of stress protein grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant activity publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-2609 – volume: 36 issue: 1 year: 2022 ident: 10.1016/j.bbagen.2023.130542_bb0040 article-title: Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer publication-title: J. Biochem. Mol. Toxicol. doi: 10.1002/jbt.22922 – volume: 70 start-page: 2657 issue: 15 year: 2013 ident: 10.1016/j.bbagen.2023.130542_bb0175 article-title: Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? publication-title: Cell. Mol. Life Sci. doi: 10.1007/s00018-012-1186-z – volume: 50 start-page: 453 issue: 1 year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0080 article-title: HYOU1 promotes cell proliferation, migration, and invasion via the PI3K/AKT/FOXO1 feedback loop in bladder cancer publication-title: Mol. Biol. Rep. doi: 10.1007/s11033-022-07978-x – volume: 79 start-page: 425 issue: 3 year: 2020 ident: 10.1016/j.bbagen.2023.130542_bb0125 article-title: METTL3 and N6-Methyladenosine promote homologous recombination-mediated repair of DSBs by modulating DNA-RNA hybrid accumulation publication-title: Mol. Cell doi: 10.1016/j.molcel.2020.06.017 – volume: 1868 issue: 4 year: 2021 ident: 10.1016/j.bbagen.2023.130542_bb0075 article-title: Long non-coding antisense RNA HYOU1-AS is essential to human breast cancer development through competitive binding hnRNPA1 to promote HYOU1 expression publication-title: Biochim. Biophys. Acta, Mol. Cell Res. doi: 10.1016/j.bbamcr.2021.118951 – volume: 88 start-page: 9429 issue: 16 year: 2014 ident: 10.1016/j.bbagen.2023.130542_bb0150 article-title: Modulation of Kaposi’s sarcoma-associated herpesvirus interleukin-6 function by hypoxia-upregulated protein 1 publication-title: J. Virol. doi: 10.1128/JVI.00511-14 – volume: 98 start-page: 1930 issue: 8 year: 1996 ident: 10.1016/j.bbagen.2023.130542_bb0065 article-title: 150-kD oxygen-regulated protein is expressed in human atherosclerotic plaques and allows mononuclear phagocytes to withstand cellular stress on exposure to hypoxia and modified low density lipoprotein publication-title: J. Clin. Invest. doi: 10.1172/JCI118994 – volume: 181-182 start-page: 47 year: 2016 ident: 10.1016/j.bbagen.2023.130542_bb0090 article-title: T-2 toxin-induced cytotoxicity and damage on TM3 Leydig cells publication-title: Comp. Biochem. Physiol. C Toxicol. Pharmacol. doi: 10.1016/j.cbpc.2015.12.005 – start-page: 9 year: 2020 ident: 10.1016/j.bbagen.2023.130542_bb0180 article-title: Imp/IGF2BP levels modulate individual neural stem cell growth and division through myc mRNA stability publication-title: Elife – volume: 40 start-page: 284 issue: 1 year: 2021 ident: 10.1016/j.bbagen.2023.130542_bb0085 article-title: ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-021-02088-1 – volume: 34 start-page: 48 issue: 1 year: 2019 ident: 10.1016/j.bbagen.2023.130542_bb0055 article-title: Enniatin B1 exerts embryotoxic effects on mouse blastocysts and induces oxidative stress and immunotoxicity during embryo development publication-title: Environ. Toxicol. doi: 10.1002/tox.22656 – volume: 22 start-page: 91 issue: 1 year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0110 article-title: The role of m6A methylation in therapy resistance in cancer publication-title: Mol. Cancer doi: 10.1186/s12943-023-01782-2 – volume: 15 start-page: 1111 issue: 5 year: 2019 ident: 10.1016/j.bbagen.2023.130542_bb0210 article-title: PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations publication-title: Hum. Vaccin. Immunother. doi: 10.1080/21645515.2019.1571892 – volume: 19 start-page: 1748 issue: 6 year: 2023 ident: 10.1016/j.bbagen.2023.130542_bb0105 article-title: Novel insights into the interplay between m6A modification and programmed cell death in cancer publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.81000 – volume: 27 start-page: 1650 issue: 10 year: 2016 ident: 10.1016/j.bbagen.2023.130542_bb0045 article-title: The Grp170 nucleotide exchange factor executes a key role during ERAD of cellular misfolded clients publication-title: Mol. Biol. Cell doi: 10.1091/mbc.E16-01-0033 – volume: 14 start-page: 1727 year: 2021 ident: 10.1016/j.bbagen.2023.130542_bb0070 article-title: Biological function of HYOU1 in tumors and other diseases publication-title: Onco Targets Ther doi: 10.2147/OTT.S297332 – volume: 18 start-page: 176 issue: 1 year: 2019 ident: 10.1016/j.bbagen.2023.130542_bb0025 article-title: Functions of N6-methyladenosine and its role in cancer publication-title: Mol. Cancer doi: 10.1186/s12943-019-1109-9 – volume: 96 start-page: e460 issue: 4 year: 2018 ident: 10.1016/j.bbagen.2023.130542_bb0060 article-title: Association of 150-kDa oxygen-regulated protein with vascular endothelial growth factor in proliferative diabetic retinopathy publication-title: Acta Ophthalmol. doi: 10.1111/aos.13600 – volume: 483 start-page: 87 year: 2020 ident: 10.1016/j.bbagen.2023.130542_bb0100 article-title: DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo publication-title: Cancer Lett. doi: 10.1016/j.canlet.2020.04.003 |
| SSID | ssj0000595 |
| Score | 2.4635606 |
| Snippet | Chemoresistance is a main reason for therapeutic failure and poor prognosis for breast cancer (BC) patients, especially for triple-negative BC patients. How... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 130542 |
| SubjectTerms | Adenine - analogs & derivatives Doxorubicin - pharmacology Humans Methyltransferases - genetics RNA, Messenger Triple Negative Breast Neoplasms |
| Title | METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38103759 https://www.proquest.com/docview/2903326523 |
| Volume | 1868 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIgQXBMurvGQkblVCEjuv47JqKavuLodUKlwi20nUVNCgbiIBh_3tzMR5rbqIhUvUuE5Seb5OPo_H3xDyNhBCBYkC7-dyafAw4YZgIjFSB77IXN926qzK0zNvvuQnK3c1Gl0Od5eU0lS_rt1X8j9WhTawK-6S_QfLdjeFBvgM9oUjWBiON7Lx6TSKFiiJ8PHDzHn_iRk7XVkeSOQ37wir3GAiUEcK55_PlzbmmWe4azcpfhS7SuLK-gTm3Mgj8U8OZxIT1UvMB1NN7m676psXap2jwMAkLScyL3RcRKAihzBbCevJRSUxutOx9S_roqqjrGuB9bmad6XWhdSuZpFvqh6mXRB7ke-3nQCem65NsMLhfbZW418DHxywZTXq19e0dU7ZCwbwYwMfC29dVyty7bl_HYnYmFJCR1S3dZjZd7-qtn12Hs-Wi0UcTVfRLXLbgWkGVsAwL_sUIaCemALb_cB262WdH7j_jKvU5g_zlZq3RA_I_WbCQY80eh6SUbo9JHd0CdKfh-TucVvx7xGRGk_v9tBEAU10iCZaZLRGE23QRAdooj2aKJxpNFGNpsdkOZtGx3OjqcFhKPD-peEnXGZMMGlL5qO4XJZ4XpBJHgaZn4ZA57mV-izzlQy5UBbPpJPYAvyTyzLoyZ6Qg22xTZ8RWq_A14Q_DDmHi31gk0o63EOaabtjwtrhi1UjUI91Ur7GbSbiJtaDHuOgx3rQx8TorvquBVr-0v9Na5kYhheXx8Q2LaqL2AktBpMZ12Fj8lSbrLsj6uAx3w2f3-DqF-ReD_2X5KDcVekrYK6lfF3D6zd-qJXz |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=METTL3%2FIGF2BP3-regulated+m6A+modification+of+HYOU1+confers+doxorubicin+resistance+in+breast+cancer&rft.jtitle=Biochimica+et+biophysica+acta.+General+subjects&rft.au=Zhou%2C+Shaocheng&rft.au=Sheng%2C+Lijuan&rft.au=Zhang%2C+Lin&rft.au=Zhang%2C+Jianan&rft.date=2024-03-01&rft.issn=1872-8006&rft.eissn=1872-8006&rft.volume=1868&rft.issue=3&rft.spage=130542&rft_id=info:doi/10.1016%2Fj.bbagen.2023.130542&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-4165&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-4165&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-4165&client=summon |